Grant: Master's Award: Canada Graduate Scholarships
University of Manitoba
$17,500.00
Identifying gut-specific downregulation of interferon-lambda receptor in ulcerative colitis patients
FY 2023-24
Summary
Ulcerative colitis (UC) is a severe life-long disease. UC gut damage involves inflammation and loss of protective gut barriers. Current drugs for UC can reduce disease symptoms and help heal the gut by inhibiting our immune system, but these drugs do not work for everyone and cause side effects. Interferon-lambdas (IFN-Ls) are unique immune proteins made in the gut to help intestinal health, even in a steady state. In mouse colitis models that can mimic gut damage seen in human UC, IFN-Ls improve the gut barrier and decrease inflammation, unlike other types of IFNs. Mice lacking Ifnlr1 and thus IFN-L signaling, also develop worse colitis. However, mouse models do not mimic all aspects of human UC. We have found in early studies that IFN-L signaling may be reduced in UC gut tissue. Whether this is due to IFN-L receptor changes or other defects remains to be tested in detail. Based on our data and mouse work, we predict that IFN-L receptor (IFN-LR) levels will be reduced in human UC, especially with active disease, compared to non-UC. This reduction in IFN-LR could worsen symptoms for patients if this mimics what others saw in mice without the IFN-LR where they had much worse colitis. In my project, I will first measure IFN-L receptor levels in control non-UC and UC patient gut tissue with or without inflammation and determine which cell types have the receptor. Next, I will measure how IFN-L promotes gut barrier and healing, which is especially important in colitis as one goal to help patients’ symptoms. I will compare non-UC and UC patient cells to see if IFN-L does not promote gut barrier function as well in UC. This work will allow us to know which patients do not respond to IFN-Ls well and eventually how we can restore IFN-L responses as a new therapy for UC.
Department
Program
Master's Award: Canada Graduate Scholarships
Recipient
Location
Manitoba, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
506438
Name
Ogungbola Uswat O
Region
Manitoba
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identifying gut-specific downregulation of interferon-lambda receptor in ulcerative colitis patients
Programtype2
Studentship Programs
Orgnameinp2
University of Manitoba
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Immunomodulation; Inflammatory Bowel Diseases (Ibd); Interferon Lambda (Ifnl); Mucosal Immunology; Type Iii Interferons; Ulcerative Colitis(Uc)
Abstract
Ulcerative colitis (UC) is a severe life-long disease. UC gut damage involves inflammation and loss of protective gut barriers. Current drugs for UC can reduce disease symptoms and help heal the gut by inhibiting our immune system, but these drugs do not work for everyone and cause side effects. Interferon-lambdas (IFN-Ls) are unique immune proteins made in the gut to help intestinal health, even in a steady state. In mouse colitis models that can mimic gut damage seen in human UC, IFN-Ls improve the gut barrier and decrease inflammation, unlike other types of IFNs. Mice lacking Ifnlr1 and thus IFN-L signaling, also develop worse colitis. However, mouse models do not mimic all aspects of human UC. We have found in early studies that IFN-L signaling may be reduced in UC gut tissue. Whether this is due to IFN-L receptor changes or other defects remains to be tested in detail. Based on our data and mouse work, we predict that IFN-L receptor (IFN-LR) levels will be reduced in human UC, especially with active disease, compared to non-UC. This reduction in IFN-LR could worsen symptoms for patients if this mimics what others saw in mice without the IFN-LR where they had much worse colitis. In my project, I will first measure IFN-L receptor levels in control non-UC and UC patient gut tissue with or without inflammation and determine which cell types have the receptor. Next, I will measure how IFN-L promotes gut barrier and healing, which is especially important in colitis as one goal to help patients’ symptoms. I will compare non-UC and UC patient cells to see if IFN-L does not promote gut barrier function as well in UC. This work will allow us to know which patients do not respond to IFN-Ls well and eventually how we can restore IFN-L responses as a new therapy for UC.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Ogungbola, Uswat O
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~